Lineage Cell Therapeutics, Inc. (LCTX) Capital expenditures 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$522,000FY2025 · since FY2016: $2.2M → $522,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $522,000 | -7.6% |
| FY2024 | $565,000 | -16.2% |
| FY2023 | $674,000 | +63.2% |
| FY2022 | $413,000 | +21.5% |
| FY2021 | $340,000 | +431.3% |
| FY2020 | $64,000 | -85.5% |
| FY2019 | $440,000 | -20.9% |
| FY2018 | $556,000 | -58.1% |
| FY2017 | $1.3M | -41.0% |
| FY2016 | $2.2M | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice